Login Register Cart 0
Generic placeholder image

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Cardiac Amyloidosis in Venezuela: A Pending Issue

Author(s): Juan Salazar*, Mayela Bracho, Carlos Esis and Roberto Añez-Ramos

Volume 20, Issue 6, 2024

Published on: 15 July, 2024

Article ID: e150724231977 Pages: 3

DOI: 10.2174/011573403X305835240715092532

Price: $65

Abstract

Cardiac amyloidosis (CA) is an infiltrative disease characterized by the deposition of misfolded proteins in cardiac interstitial tissue. Interest towards studying this pathology has been growing in the last decade, as new epidemiological insights have revealed that it is not as uncommon as previously believed. Likewise, advances in non-invasive diagnostic approaches and the identification of molecules that modify its long-term progression, even in terms of mortality, have also bolstered interest in CA. Despite this global panorama, in Venezuela, limitations remain regarding the diagnosis of CA, partly associated with a lack of knowledge of the disease. Therefore, additional efforts are necessary for clinical cardiologists to hone their diagnostic skills regarding this disease, as opportune identification is an essential step for its effective management.

[1]
Buxbaum JN, Dispenzieri A, Eisenberg DS, et al. Amyloid nomenclature 2022: Update, novel proteins, and recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid 2022; 29(4): 213-9.
[http://dx.doi.org/10.1080/13506129.2022.2147636] [PMID: 36420821]
[2]
Aimo A, Merlo M, Porcari A, et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. Eur J Heart Fail 2022; 24(12): 2342-51.
[http://dx.doi.org/10.1002/ejhf.2532] [PMID: 35509173]
[3]
Allegra A, Mirabile G, Tonacci A, Genovese S, Pioggia G, Gangemi S. Machine learning approaches in diagnosis, prognosis and treatment selection of cardiac amyloidosis. Int J Mol Sci 2023; 24(6): 5680.
[http://dx.doi.org/10.3390/ijms24065680] [PMID: 36982754]
[4]
Suárez JA, Puigbo JJ, Nava JR, Valero J, Gil C. Estudio anatomopatológico de 210 casos de miocardiopatías en Venezuela. Acta Medica Venezolana 1968; 15(11): 320-30.
[5]
Arrioja A, Velazco L, Aguilar R, Flores Y, Ramírez A. Amiloidosis cardíaca. Adv Cardiol 2020; 40(2): 144-5.
[6]
Mut F, Carvajal I, Camilletti J, Erriest J, Alexanderson E, Grossman GB. Cardiac amyloidosis in latin america: Gaps and opportunities to increase awareness of the disease. Findings from the AMILO-LATAM research group. J Nucl Cardiol 2023; 30(4): 1592-601.
[http://dx.doi.org/10.1007/s12350-022-03005-5] [PMID: 35641695]
[7]
García-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 2021; 42(16): 1554-68.
[http://dx.doi.org/10.1093/eurheartj/ehab072] [PMID: 33825853]
[8]
Kittleson MM, Ruberg FL, Ambardekar AV, et al. Writing committee. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis. J Am Coll Cardiol 2023; 81(11): 1076-126.
[http://dx.doi.org/10.1016/j.jacc.2022.11.022] [PMID: 36697326]
[9]
Brito D, Albrecht FC, de Arenaza DP, et al. World heart federation consensus on transthyretin amyloidosis cardiomyopathy (ATTR-CM). Glob Heart 2023; 18(1): 59.
[http://dx.doi.org/10.5334/gh.1262] [PMID: 37901600]
[10]
Miller P, Maurer MS, Poterucha T. Socioeconomic disparities prevent equitable Tafamidis access in transthyretin cardiac amyloidosis. J Am Coll Cardiol 2023; 81(8) (Suppl.): 342.
[http://dx.doi.org/10.1016/S0735-1097(23)00786-6]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy